SCHEMBL29501239

SCHEMBL29501239

CC(C)Oc1cccc(-c2cccnc2OC(F)F)c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALOX5AP P20292 7/20 0.50
FEN1 P39748 7/20 0.50
FFAR4 Q5NUL3 4/20 0.43
PDE4B Q07343 4/20 0.42
PDE4A P27815 3/20 0.42
PDE4C Q08493 3/20 0.42
PDE4D Q08499 3/20 0.42
NR3C1 P04150 1/20 0.42
PGR P06401 1/20 0.42
RXRA P19793 1/20 0.42
RXRB P28702 1/20 0.42
GABRA1 P14867 1/20 0.41
GABRG2 P18507 1/20 0.41
GABRB3 P28472 1/20 0.41
GABRA5 P31644 1/20 0.41
GABRA3 P34903 1/20 0.41
PIM1 P11309 1/20 0.41
PIM3 Q86V86 1/20 0.41
PIM2 Q9P1W9 1/20 0.41
PDE5A O76074 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29501226 0.88 DYRK1A (0.53) ALOX5APFEN1PDE4BPDE4APDE4C
SCHEMBL29501219 0.85 ALOX5AP (0.47) ALOX5APFEN1FFAR4PDE4BPDE4A
SCHEMBL29501200 0.83 PDE4B (0.46) FFAR4PDE4BPDE4APDE4CPDE4D
SCHEMBL29501216 0.79 TRPV4 (0.46) ALOX5APFEN1PDE4BPDE4APDE4C
SCHEMBL29501221 0.78 FFAR4 (0.42) ALOX5APFEN1FFAR4PDE4BPDE4A
SCHEMBL16044623 0.78 PDE10A (0.40) FFAR4PDE4BPDE4APDE4CPDE4D
SCHEMBL29501234 0.76 ALOX5AP (0.52) ALOX5APFEN1FFAR4PDE4BPDE4A
SCHEMBL29501208 0.74 TRPV4 (0.43) ALOX5APFEN1PDE4BPDE4APDE4C
SCHEMBL16044370 0.74 DHFR (0.46) ALOX5APFEN1PDE4BPDE4APDE4C
SCHEMBL29501224 0.74 PDE10A (0.47) ALOX5APFEN1NR3C1PGR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250122172-A1 SUBSTITUTED PYRIDINE AND PYRAZINE COMPOUNDS AS PDE4 INHIBITORS DART NEUROSCIENCE LLC 2025-04-17 US disclosed
US-20230075774-A1 SUBSTITUTED PYRIDINE AND PYRAZINE COMPOUNDS AS PDE4 INHIBITORS DART NEUROSCIENCE LLC (US) 2023-03-09 US disclosed
US-11279691-B2 Substituted pyridine and pyrazine compounds as PDE4 inhibitors DART NEUROSCIENCE LLC (US) 2022-03-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250122172-A1 SUBSTITUTED PYRIDINE AND PYRAZINE COMPOUNDS AS PDE4 INHIBITORS PDE4A, PDE4B, PDE4D ALOX5AP 3254/4885FEN1 4136/4885FFAR4 133/4885
US-20230075774-A1 SUBSTITUTED PYRIDINE AND PYRAZINE COMPOUNDS AS PDE4 INHIBITORS PDE4A, PDE4B, PDE4D ALOX5AP 3254/4885FEN1 4136/4885FFAR4 133/4885
US-11279691-B2 Substituted pyridine and pyrazine compounds as PDE4 inhibitors PDE4A, PDE4B, PDE4D ALOX5AP 3204/4885FEN1 4105/4885FFAR4 133/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.